



1614

Please type a plus sign (+) inside this box.

PTO/SB/21 (08-00)  
Approved for use through 10/31/02. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/028,181
	Filing Date	December 21, 2001
	First Named Inventor	Harry PRINCE et al
	Group Art Unit	1614
	Examiner Name	To be assigned
Total Number Of Pages In This Submission	Attorney Docket No.	524902000200

RECEIVED

AUG 05 2002

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement; Form 1449 and 29 references.	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Peng Chen Morrison & Foester 3811 Valley Centre Drive, Suite 500, San Diego, California 92130
Signature	
Date	July 23, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on July 23, 2002.

Susan B. Lynch


Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



PATENT  
Docket No. 524902000200

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on July 23, 2002.

  
Susan B. Lynch

#15  
RECEIVED  
AUG 05 2002  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Harry PRINCE et al.

Serial No.: 10/028,181

Filing Date: December 21, 2001

For: OXIDIZED FUNGAL ANTIGENS AND  
METHODS OF MAKING AND USING  
THEREOF

Examiner: To be assigned

Group Art Unit: 1614

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

☐ With the application; accordingly, no fee or separate requirements are required.

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of \* is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of \* is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this

document to Deposit Account No. 03-1952 referencing 524902000200. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 23, 2002

Respectfully submitted,

By:   
Peng Chen  
Registration No. (43,543)

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5117  
Facsimile: (858) 720-5125

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Docket Number 524902000200	Application Number 10/028,181
	Applicant Harry PRINCE et al.	
	Filing Date 21 December 2001	Group Art Unit 1614
	Mailing Date July 23, 2002	



RECEIVED  
AUG 05 2002  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	04/12/1994	US 5,302,509	Cheeseman	435	6	
	2.	12/30/1997	US 5,703,055	Felgner et al.	514	44	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	3.	Bosin and Kasper (1992). <i>Toxicol.</i> 7(3):139-45.
	4.	Brock and Madigan (1991). In: <u>Biology of Microorganisms</u> (6th Ed.). Prentice Hall, Englewood Cliffs, New Jersey 07632, pp. 817-818.
	5.	Bullock (1995). In: <u>Principles and Practice of Infectious Diseases</u> , GL Mandell et al. (eds), Churchill Livingstone, New York. pp. 2340-2353 and 2365-2375.
	6.	Casadevall, Arturo (1995). <i>Infec and Imm</i> 63(11):4211-4218.
	7.	Fatiadi, A.J. (1974). <i>Synthesis</i> 229.
	8.	Fisher et al. (1997). <i>Mycroses</i> 40:83-90.
	9.	Focus Technologies (2001). <i>Histoplasma capsulatum IgG Assay Tech Sheet</i>
	10.	Galgiani (1999). <i>Ann. Intern. Med.</i> 130:293-300.
	11.	Im et al. (1985). <i>J. Biol. Chem.</i> 260(8):4591-7.
	12.	Kaufman et al. (1995). <i>J. Clin. Microbiol.</i> 33(3):618-619.
	13.	Marzulli et al. (1985). <i>Boll Soc. Ital. Biol. Sper.</i> 61(1):121-7.
	14.	Pan and Jordan (1998). <i>Biochemistry</i> 37(5):1357-64.
	15.	Pizzini et al. (1999). <i>Clin. Diagn. Lab. Immunol.</i> 6(1):20-23.
	16.	Saha et al. (1989). <i>Int. J. Rad. Appl. Instrum.</i> 16(4):431-3.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 524902000200	Application Number 10/028,181
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Harry PRINCE et al.	
		Filing Date 21 December 2001	Group Art Unit 1614
		Mailing Date July 23, 2002	
	17.	Santini et al. (1996). <i>Free Radic. Biol. Med.</i> 20(7):915-24.	
	18.	Siebert, H. (1967). <i>Fortschr. Chem. Forsch.</i> 8:470.	
	19.	Sinn et al. (1988). <i>Anal. Biochem.</i> 170(1):186-92.	
	20.	Stevens (1995). <i>N. Engl. J. Med.</i> 332:1077-1082.	
	21.	Tarin et al. (1996). <i>Mol. Hum. Reprod.</i> 2(12):895-901.	
	22.	Wenzel and Pfaller (1991). <i>Infect. Control Hosp. Epidemiol</i> 12:523-524.	
	23.	Willard (1939). <i>Inorg. Syn.</i> 1:172.	
	24.	Wozniak et al. (1998). <i>Bioorg. Med. Chem. Lett.</i> 8(19):2641-6.	
	25.	Yang et al. (1997). <i>Clin. Diagn. Immunol.</i> 4:19-22.	
	26.	Zancope-Oliveria et al. (1994). <i>Clin. Diagn. Lab. Immunol.</i> 1(4):390-93.	
	27.	Zancope-Oliveria et al. (1994). <i>Clin. Diagn. Lab. Immunol.</i> 1(5):563-568.	
	28.	Zartarian et al. (1997). <i>Am J. Clin. Pathol.</i> 207:148-153.	
	29.	Zierdt, Charles H. (1995). <i>Journ of Parasitology</i> 81(1):127-129.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			